Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
look here
Popular Articles
Natural Remedies

U.S. Bill Would Establish Survey To Collect Health Data From Native Hawaiians, Pacific Islanders
Madeleine Bordallo, the U.S. delegate from Guam, has introduced legislation that would fund a survey to collect health data from Native Hawaiians and Pacific Islanders, the Pacific Daily News reports. The legislation would amend the Public Health Service Act to fund the survey through HHS.Bordallo said, "Native Hawaiian and Pacific Islander communities are eager to move forward with their efforts to improve public health. This scientific survey would establish baseline health information to inform health policy and interventions so that individual and community health can be properly tracked and evaluated." According to the Daily News, while federal agencies should be collecting data on native Hawaiians and Pacific Islanders separately from Asian-Americans, most have not done so (Limtiaco, Pacific Daily News, 5/26).
generic viagra online
WHO Raises Pandemic Alert To Phase 6, Director General Gives Speech
The World Health Organization (WHO) announced it has raised the level of influenza pandemic alert from phase 5 to phase 6, following an
News of the day
Actual Imaging Use Far Below President's Recommend 95 Percent Utilization Rate For Medicare
The amount of time imaging equipment is in use in outpatient settings does not approach use rates President Obama and the Medicare Payment Advisory Commission (MedPAC) recommend Medicare utilize to calculate reimbursement for imaging, according to data recently collected by the Radiology Business Management Association (RBMA), a national association of business professionals in radiology.
Medical Devices

Bosentan Is Cost-Effective For Patients With Moderate PAH

Bosentan appears to be a more cost-effective initial treatment option for patients with moderate pulmonary arterial hypertension (PAH), classified as WHO functional class III, than no active intervention. A cost-utility model was constructed to evaluate the cost-effectiveness of bosentan compared with no active intervention, both added to palliative care in the UK. In the model, simulated patients remained on their initial intervention until death or until they deteriorated to functional class IV, which triggered initiation of intravenous epoprostenol treatment. In the base-case analysis, which assumed that first line treatment did not affect survival, bosentan was more effective and less costly than no active intervention. When survival benefits associated with bosentan treatment were taken into consideration, bosentan was found to be a potential cost effective first line treatment. The work, led by Matt Stevenson was conducted at the University of Sheffield. Dr Stevenson commented: "Long-term follow-up data from randomised controlled trials show that bosentan significantly delays progression to more severe states compared with no active intervention. This results in both potential cost-savings due to a reduction in the duration of relatively expensive epoprostenol treatment and in an improvement in the quality of life for patients." This study is published in Value in Health, the official journal of the International Society for Pharmacoeconomics and Outcomes Research. Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research and help health care leaders to make decisions that are solidly evidence-based. The journal is published bi-monthly and has a regular readership of over 4,000 clinicians, decision-makers, and researchers worldwide. ISPOR is a nonprofit, international organization that strives to translate pharmacoeconomics and outcomes research into practice to ensure that society allocates scarce health care res wisely, fairly, and efficiently. ISPOR


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009